@article{3212432,
    title = "The ten commandments of chemoembolization: expert discussion and report from Mediterranean Interventional Oncology (MIOLive) congress 2017.",
    author = "Malagari, K. and Iezzi, R. and Goldberg, S. N. and Bilbao, J. I. and Sami, A. and Akhan, O. and Giuliante, F. and Pompili, M. and Crocetti, L. and Valentini, V. and Gasbarrini, A. and Colosimo, C. and Manfredi, R.",
    journal = "European Review for Medical and Pharmacological Sciences",
    year = "2018",
    volume = "22",
    number = "2",
    pages = "372--381",
    issn = "1128-3602, 2284-0729",
    doi = "10.26355/eurrev_201801_14184",
    keywords = "Humans, Neoplasm Recurrence, Local, Patient Selection, *Chemoembolization, Therapeutic/adverse effects, Carcinoma, Hepatocellular/pathology/*therapy, Congresses as Topic, Ethiodized Oil/chemistry, Liver Neoplasms/pathology/*therapy",
    abstract = "Transarterial therapies in the setting of primary and secondary liver malignancies are becoming an essential part of the oncology landscape. The mechanism of action of  c-TACE is the induction of tumor necrosis due to the high concentration of the  chemotherapeutic that is delivered only locally and to the embolic effect that  causes ischemia and increased dwell time of the chemotherapeutic in the tumor.  Recently, DEB-TACE has emerged as a variation of c-TACE with the potential for the  selective delivery of large amounts of drugs to the tumor for a prolonged period,  thereby decreasing plasma levels of the chemotherapeutic agent and related systemic  effects. There is an increasing consensus that compared with conventional  lipiodol-based regimen, DEB-TACE offers standardized methodology, is more  reproducible and is associated with improved response and significantly better  safety profile. Using an easy to access point by point format, this manuscript  summarizes the expert discussion from the Mediterranean Interventional Oncology Live  Congress (MIOLive 2017) about the role of TACE in the treatment of liver tumors."
}